Medinotec Inc.
MDNCdata completeness 88%4 fiscal years on fileData notes: no data for concept 'totalDebt'; no data for concept 'epsDiluted'
Medinotec Inc. earns about 126% on invested capital, far above its ~9% cost of capital, but has diluted owners by 100084% over 4 years — a real edge showing up in the numbers. The estimate methods put fair value between $0.19 and $4.24 a share.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.
| Figure | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|
| Revenue | $999,5791 | $5.02M2 | $9.11M3 | $9.73M3 |
| Net income | −$352,7354 | −$404,6885 | $2.16M6 | $794,5026 |
| Operating cash flow | −$490,5497 | $14,2428 | $877,8349 | $906,7989 |
| Capital expenditure | $55,27710 | −$2,25511 | $89,01312 | $1,36312 |
| Free cash flow (derived) | −$545,8267 | $16,4978 | $788,8219 | $905,4359 |
| Total debt | — | — | — | — |
| Cash & equivalents | $2.83M13 | $2.81M14 | $2.77M14 | $2.76M14 |
| Diluted shares | 11,734 | 11.7M | 11.7M | 11.8M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
10 shares is a claim on $4.86 of net worth that earned you $0.68 and generated $0.77 of cash last year.
It earned about 126% on invested capital, year after year, against a ~9% cost of capital — the footprint of real pricing power. Competition usually drags returns like this back down; here it hasn't.
seeing a moat in the numbers →Share count is up 100084% over 4 years — owners have been diluted. Worth asking what they got for it.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
The 3 estimate methods that apply put fair value between $0.19 and $4.24 a share. They rest on different assumptions, so where they diverge is the story.
assumptions (10)
- riskFreeRate4.7%
- equityRiskPremium5.0%
- beta100.0%
- equityWeight85.0%
- costOfDebtSpread1.5%
- taxRate21.0%
- terminalGrowth2.5%
- projectionYears10
- fcfGrowth20.0%
- fcfBase$788,821
assumptions (10)
- riskFreeRate4.7%
- equityRiskPremium5.0%
- beta100.0%
- equityWeight85.0%
- costOfDebtSpread1.5%
- taxRate21.0%
- terminalGrowth2.5%
- projectionYears5
- fcfGrowth20.0%
- fcfBase$788,821
assumptions (8)
- riskFreeRate4.7%
- equityRiskPremium5.0%
- beta100.0%
- equityWeight85.0%
- costOfDebtSpread1.5%
- taxRate21.0%
- normalizedEarnings$220,883.5
- growthAssumed0.0%
Different models answer different questions — which to trust when →
| Bear | 0.0% | $1.19 |
| Base | 20.0% | $2.42 |
| Bull | 20.0% | $2.42 |
Bear/base/bull growth = 0% / filed history / history + 5pp. Type a price to see the return each case implies.
Default growth 20.0%= this company’s own filed history (median-to-median FCF CAGR, clamped 0–20%). Your adjustments are recorded anonymously. They become the “what do owners actually believe” dataset.
- 10-K · period ending 2023-02-28 · accession 0001663577-24-000168 (Revenues)
- 10-K · period ending 2024-02-29 · accession 0001663577-25-000171 (Revenues)
- 10-K · period ending 2025-02-28 · accession 0001663577-26-000175 (Revenues)
- 10-K · period ending 2023-02-28 · accession 0001663577-24-000168 (NetIncomeLoss)
- 10-K · period ending 2024-02-29 · accession 0001663577-25-000171 (NetIncomeLoss)
- 10-K · period ending 2025-02-28 · accession 0001663577-26-000175 (NetIncomeLoss)
- 10-K · period ending 2023-02-28 · accession 0001663577-24-000168 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2024-02-29 · accession 0001663577-25-000171 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2025-02-28 · accession 0001663577-26-000175 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2023-02-28 · accession 0001663577-24-000168 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2024-02-29 · accession 0001663577-25-000171 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2025-02-28 · accession 0001663577-26-000175 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2023-02-28 · accession 0001663577-25-000171 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)
- 10-K · period ending 2024-02-29 · accession 0001663577-26-000175 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)